A large cancer clinical trial is investigating whether adding sargramostim, an immunomodulatory cytokine, to dual immunotherapy consisting of nivolumab and ipilimumab can improve outcomes for patients with metastatic melanoma. It builds earlier evidence suggesting this approach may enhance survival while reducing toxicity. Patient follow-up is ongoing.

A new editorial published in JAMA Oncology warns that cancer care progress is under threat from a "trifecta" of challenges: proposed federal budget cuts, a surge in medical misinformation, and a critical gap in public health literacy.

A research group led by Professor Cecilia Sahlgren at Åbo Akademi University in Finland and the InFLAMES Research Flagship has identified a new mechanism directing the adverse remodeling of tumor tissue during breast cancer progression. This discovery could offer new treatment opportunities against aggressive forms of breast cancer which currently lack targeted therapy options.